Navigation Links
CVS Caremark Developing New Ways to Help Patients Take Medications as Directed

WASHINGTON, May 26, 2011 /PRNewswire/ -- Researchers at Harvard University, Brigham and Women's Hospital and CVS Caremark today outlined their findings on the issue of medication adherence and made recommendations for how their research to date can be used to help improve the way pharmacy care is delivered in the U.S.  The research collaboration between these groups was announced in the fall of 2009 and was showcased today at a forum at the National Press Club in Washington, D.C. marking the half-way point in the three-year-initiative.  


In addition to reviewing results to date, the research team leaders urged regulators and legislators to renew their focus on making sure people take their medications as directed by their physicians as a way to improve the quality of care and reduce costs for caring for the chronically ill.  Annual excess health care costs due to medication non-adherence in the U.S. have been estimated to be as much as $300 billion annually.

"When we began, we knew our research would expand the science of pharmacy care," said Troyen A. Brennan, MD, MPH executive vice president and chief medical officer of CVS Caremark, who heads the research initiative. "The more we studied the topic, the more we realized that there are steps our industry can take today to improve the rates at which people take their medicines. This is important work because we know if we can improve medication adherence rates, we have a unique opportunity to improve the quality and lower the cost of health care."

"Not surprisingly, we learned there is no single answer to solving the puzzle of adherence, even though this problem has been recognized for decades. But there are practices we can improve upon and programs we can implement that can have an impact. That work can start today," said William H. Shrank, MD, MSHS, who heads the research project for Brigham and Women's Hospital and Harvard Medical School.

Among the recommendations called for by the research team are:

  • Developing tools through continued research that will allow pharmacists to predict and target those patients who are at risk for non-adherence and prescription abandonment so pharmacists can proactively intervene to improve their care.
  • Working with pharmacists and other health care providers to simplify pharmacy care for those with the most complex therapies by utilizing a "pharmacy home" concept where one health care professional works with the rest of the medical team to manage and synchronize a patient's medication therapy.
  • Improving pharmacist and health care provider communications with patients to enhance adherence through individualized counseling.
  • Researching the use of financial or other incentives to encourage adherence because immediate, positive reinforcement for the right behavior can be a powerful motivator to change behavior.
  • Developing a personalized medication approach, such as through pharmacogenomics or individualized counseling with pharmacists, to best deliver pharmacy care.
  • Studying social networks and connections to see how they can be utilized to improve medication use by individuals seeking help and advice from family and friends.

In addition, there are policy initiatives the industry and Congress can promote to make sure people are aware of the importance of taking their medicines the right way. Those proposals include:

  • Making the goal of improving medication adherence a national priority and encouraging  legislative policies to promote education and incent provider and patient behavior;
  • Leveraging investments in innovative technologies to make adherence simple; and
  • Supporting continued public/private partnerships to remove cost barriers and undesirable patient behavior.

A webcast of "Advancing Adherence and the Science of Pharmacy Care," a forum held today at the National Press Club, is available at

About CVS Caremark

CVS Caremark is the largest pharmacy health care provider in the United States with integrated offerings across the entire spectrum of pharmacy care. We are uniquely positioned to engage plan members in behaviors that improve their health and to lower overall health care costs for health plans, plan sponsors and their members. CVS Caremark is a market leader in mail order pharmacy, retail pharmacy, specialty pharmacy, and retail clinics, and is a leading provider of Medicare Part D Prescription Drug Plans. As one of the country's largest pharmacy benefits managers (PBMs), we provide access to a network of approximately 65,000 pharmacies, including more than 7,200 CVS/pharmacy® stores that provide unparalleled service and capabilities. Our clinical offerings include our signature Pharmacy Advisor™ program as well as innovative generic step therapy and genetic benefit management programs that promote more cost effective and healthier behaviors and improve health care outcomes. General information about CVS Caremark is available through the Company's website at

Media Contact:
Jon Sandberg
CVS Caremark
(401)770 4914

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CVS Caremark Research Tailors Consumer Communications to Encourage Better Medication Behavior
2. CVS Caremark to Present at the Sanford C. Bernstein Strategic Decisions Conference
3. CVS Caremark to Participate in the Citi Investment Research 2011 Global Consumer Conference
4. CVS Caremark to Pilot Electronic Prior Authorization to Help Speed Patient Access to Prescription Medication
5. CVS Caremark Named as Finalist for 2011 URAC Award for Best Practices in Health Care Consumer Empowerment and Protection
6. CVS Caremark Uniquely Integrated Business Well-Positioned to Deliver Shareholder Value
7. CVS Caremark Reports First Quarter Results
8. CVS Caremark to Complete Acquisition of Universal Americans Medicare Part D Business
9. NCPA Responds to Consumer Groups Request for CVS Caremark Divestiture
10. CVS Caremark to Offer Medical Benefit Drug Management Services to Clients
11. CVS Caremark Insights 2011 Report Highlights Lowest Drug Trend in Six Years and Increased Utilization of Generics
Post Your Comments:
(Date:10/8/2015)... Oct. 8, 2015  Clariant, a world leader in specialty ... facility in Belen, New Mexico , has ... including desiccant canisters and packets and other ... plant is the second Clariant site – the first in ... the ISO 15378:2011 standards, following only the Clariant manufacturing facility ...
(Date:10/8/2015)... , Oct. 8, 2015  Nektar Therapeutics (Nasdaq: ... pain and oncology portfolio during an Investor and Analyst ... p.m. Eastern Time in New York City ... of the NKTR-214 Phase 1/2 clinical program and biomarker ... cytokine designed to preferentially stimulate the production of CD8-positive ...
(Date:10/8/2015)... a clinical stage drug development company focused on advancing ... today the commencement of the US arm of an ... acebilustat, in patients with cystic fibrosis (CF). The study ... the United States and European Union, ... 2016. This landmark clinical trial testing once-daily oral acebilustat ...
Breaking Medicine Technology:
... Texas, Dec. 2, 2010 Ascension Orthopedics, Inc., ... another implantation of the TITAN™ Modular Total Shoulder. ... at Bucks County Specialty Hospital in Bensalem, Pennsylvania. ... postoperative x-rays showed a very anatomic replacement.  The ...
... 2, 2010 Medical devices, biotechnology and IT products ... will present to United States investors and the business ... business and investment opportunities. (Logo: ... successful Chilean Small and Medium Enterprises (SMEs) was selected ...
Cached Medicine Technology:
(Date:10/10/2015)... York, NY (PRWEB) , ... October 10, 2015 , ... ... some alarming numbers on the growth of cybercrime costs for US companies. The New ... on Tuesday, October 6th. With averages showing increases hovering around 20% among the companies ...
(Date:10/10/2015)... , ... October 10, 2015 , ... Isabel Healthcare will ... , On the heels of the release of the Institute of Medicine’s latest report ... their integration with Cerner solutions that assist healthcare providers and consumers to potentially reduce ...
(Date:10/9/2015)... ... October 09, 2015 , ... The American Osteopathic ... for Graduate Medical Education J. Michael Finley, DO, as the recipient of the ... for his impact on graduate medical education opportunities for osteopathic residents, and his ...
(Date:10/9/2015)... ... 2015 , ... A new health tool that helps identify if a sore ... ) – just in time for the cold and flu season, which the ... many in the U.S., the real start of cold/flu season is the start of ...
(Date:10/9/2015)... ... October 09, 2015 , ... Dentist in Huntington ... orthodontic system that uses clear, plastic aligners. This alternative to braces has become ... which allow patients to complete treatment in privacy. Additionally, Invisalign aligners are removable, ...
Breaking Medicine News(10 mins):
... serious problem that can often be fatal. Methadone has ... addicts. However, the major concern in treating heroin addicts ... is one reason methadone therapy is usually only given ... that an alternative drug therapy combined with psychosocial treatment ...
... researchers are currently testing the safety of hypothermia ... injury. Hypothermia treatment has been shown to be ... but its effectiveness in treating children with traumatic ... decreases inflammation, excitotoxicity (excessive neurotransmitters released with injury ...
... of skin cancer and it has been shown through previous ... sunlight, whose UV rays cause damage to DNA that triggers ... are more prone than others to melanoma. Researchers have now ... people with melanoma that those with fair skin// have lowered ...
... Affective Disorder(SAD) is not all that well understood, but ... sunlight in the winter months. Winter depression involves suffering ... days get longer and nights get shorter. Other SAD ... sleeping for longer than usual. Researchers have now found ...
... hospital in Kolkatta, India recently received a patient, a two-month-old ... suffering from a rare disease caused due to a deficiency ... of 10 million children. Doctors said that the baby was ... On detection the baby, a boy child, was found to ...
... time to its ultraviolet rays, has always been said to be ... shown that even moderate sun exposure can result in moles that ... to sun has been shown as the main risk factor for ... rarest type of skin cancer, is much weaker. It has however, ...
Cached Medicine News:
The IRN method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of iron in serum....
For the quantitative in vitro determination of Aspartate Aminotransferase (AST) in serum and plasma....
Enzymatic Clearance assay for the in vitro quantitative determination of HDL-cholesterol in human serum and plasma....
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Medicine Products: